Intuitive Surgical Q3 Non-GAAP Earnings, Revenue Increase

/ / Health Care /

Intuitive Surgical (ISRG) reported late Thursday Q3 non-GAAP earnings of $1.46 per diluted share, up from $1.19 a year earlier. Analysts polled by Capital IQ expected $1.42. Revenue for the quarter ended Sept. 30 was $1.74 billion, up from $1.56 billion a year earlier. Analysts surveyed by Capital IQ expected $1.77 billion.

Intuitive Surgical Q3 Non-GAAP Earnings, Revenue Increase Read Post »

Schlumberger (NYSE:SLB) Q3 Adj. EPS $0.78 Beats $0.77 Estimate, Sales $8.31B Miss $8.33B Estimate

/ / Energy /

Schlumberger (NYSE:SLB) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.77 by 1.3 percent. This is a 23.81 percent increase over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $8.31 billion which missed the analyst consensus estimate of $8.33 billion by 0.24 percent. This is a 11.14 percent increase over sales of $7.48 billion the same period last year.

Schlumberger (NYSE:SLB) Q3 Adj. EPS $0.78 Beats $0.77 Estimate, Sales $8.31B Miss $8.33B Estimate Read Post »

CFRA Keeps Sell Opinion On Shares Of Comerica Incorporated

/ / Financials /

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We decrease our 12-month target price by $3 to $35, 5.8x our 2024 EPS estimate, a discount to CMA’s five-year forward P/E average of 11.5x given elevated funding pressure. We increase our 2023 EPS estimate by $0.16 to $7.79 and lower 2024’s by $0.09 to $6.02. CMA posted Q3 EPS of $1.84 versus $2.60 a year ago, $0.14 above consensus. Net interest income fell 3% Q/Q as the bank’s net interest margin compressed 9 bps to 2.84%. After six straight quarters of sequential deposit outflows, balances rebounded with 2% Q/Q growth. However, noninterest-bearing balances fell 5% and we expect continued pressure as clients continue to search for yield in today’s high-rate environment. Credit quality continued to impress with nonperforming assets falling 4 bps to 0.29%. Capital levels

CFRA Keeps Sell Opinion On Shares Of Comerica Incorporated Read Post »

Amgen Reports ‘Encouraging’ Results From Phase 2 Tarlatamab Study for Lung Cancer

/ / Health Care /

Amgen (AMGN) on Friday said its global phase 2 study of tarlatamab in patients with advanced stage small cell lung cancer showed that the investigational drug delivered an “encouraging” objective response rate of 40% and median overall survival of 14.3 months. “In the current third-line treatment of SCLC, patients face a dire prognosis, with response rates ranging between 14 and 21 percent and median overall survival less than six months,” said Luis Paz-Ares, head of the lung cancer unit at the National Oncology Research Center. Amgen said no new safety concerns were reported and there were only 4% discontinuations due to treatment-related adverse events. Tarlatamab is an investigational drug targeting the BiTE, or bi-specific T-cell engager, molecule, directing them toward tumor-specific antigens, and activating their cytotoxic capabilities to eradicate cancer, according to the company.

Amgen Reports ‘Encouraging’ Results From Phase 2 Tarlatamab Study for Lung Cancer Read Post »

Scroll to Top